It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension in the trading of the securities of BioXyTran, Inc. (“BIXT”) (CIK No. 0001445815) because of questions regarding the accuracy and adequacy of information in the marketplace concerning BIXT since at least February 5, 2020. Questions regarding information in the marketplace relate to statements about BIXT’s present ability to develop a drug to mitigate or treat COVID-19 that BIXT made in press releases, blog posts, and a podcast between February 5 and March 25, 2020. Further concerns relate to possible manipulative trading of BIXT’s stock, including certain transactions executed between January 21 and February 28, 2020.

BIXT is a Nevada corporation whose principal place of business is in Newton, MA. BIXT’s common shares are registered with the Commission under Section 12(g) of the Securities Exchange Act of 1934 and are quoted on OTC Link (previously Pink Sheets) operated by OTC Markets Group Inc., under the symbol BIXT. As of April 7, 2020, BIXT had eleven market makers and was eligible for the “piggyback” exception of Rule 15c2-11(f)(3) under the Securities Exchange Act of 1934. The Commission is of the opinion that the public interest and
the protection of investors require a suspension of trading in the securities of the above-listed company.

THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EDT, on April 16, 2020 through 11:59 p.m. EDT, on April 29, 2020.

By the Commission.  

Vanessa A. Countryman  
Secretary